Summary
Introduction
Phenformin lowers the blood glucose concentration of maturity-onset diabetic subjects (Craig, Miller, Woodward & Merik, 1960 ; Fajans, Moorhouse, Doorenbos, Louis & COM, 1960) , but increases the blood concentrations of lactate, pyruvate, alanine and the lactate/pyruvate ratio (Varma, Heaney, Whyte & Walker, 1972; Nattrass, Todd, Hinks, Lloyd & Albcrti, 1977) .
However, phenformin does not lower the blood glucose concentration of normal subjects (Fajans et af., 1960) unless administration is combined with prolonged fasting (Lyngsm & Trap-Jensen, 1969 We have studied the metabolic effects of phenformin in normal subjects and their relationship to plasma phenformin concentration.
Methods

Subjects
Six healthy volunteer subjects (age range 21-61 years; percentage ideal body weight 90-137) were studied. None had evidence of hepatic or renal impairment, as judged by routine liver and renal function tests, and none had a firstdegree relative with diabetes mellitus. All gave informed consent and the study was approved by the local Ethical Committee.
Procedure
Each subject was studied on two occasions a? least a month apart. On the day of the study, after an overnight fast, an indwelling intravenous cannula was inserted into an antecubital vein at 08.25 hours and at 08.30 hours breakfast was eaten. At the beginning of breakfast, phenformin (50 mg sustained-release capsule) or placebo of identical appearance was taken. The order of the two studies was randomized. Blood samples were withdrawn at 08.30 and 09.00 hours and hourly until 18.00 hours. Lunch was eaten at 12.05 hours and snacks at 10.05 and 15.05 hours, and each subject ate a diet of identical carbohydrate and calorific content on the 2 days of the study. Subjects were encouraged to take gentle exercise between samples, but rested for 10 min before each blood sample.
Blood sampling procedure and assays. At each sample time approximately 8 ml of blood was withdrawn; 1-2 ml was mixed with ice-cold 5% (v/v) perchloric acid and refrigerated; 3-4 ml was placed in a lithium/heparin tube (Searle Diagnostics, High Wycombe, Bucks, U.K.), centrifuged, and plasma separated immediately and stored at -2OOC for plasma phenformin assay. The remainder of the blood was allowed to clot, and serum was separated and stored at -2OOC for subsequent insulin assay.
Glucose, lactate, pyruvate, alanine, glycerol and 3-hydroxybutyrate were assayed in the perchloric acid extract by automated enzymic fluorimetric assays (Lloyd, Burrin, Smythe & Alberti, 1978) . Acetoacetate was assayed in the perchloric acid extract by the kinetic, spectrophotometric method (Price, Lloyd & Alberti, 1977) . Plasma phenformin was assayed by gashquid chromatography (Mottale & Stewart, 1975) and serum insulin by double-antibody radioimmunoassay (Soeldner & Slone, 1965) .
Statistical analysis. The average concentration during the study for each patient has been used to derive the mean f SEM for the six subjects. Significant differences between studies have been sought by using Wilcoxon's rank sum test. Significant correlations were sought for plasma phenformin concentration and the differences in concentrations of metabolite on placebo and on phenformin by Spearman's rank correlation.
Results
There were no significant differences in fasting metabolite or hormone concentrations on the 2 study days.
The minimum detectable concentration of phenformin in plasma was 0.05 ,umol/l and it was not reached in our subjects until 0.5-1.5 h after ingestion of a 50 mg sustained-release capsule. Thereafter concentrations ranged up to 0.29 ,umol/l with the mean peak concentration occurring 3.5 h after ingestion (0-19 i-0.03 ,umol/l; mean f. SEM).
Plasma phenformin concentration 9.5 h after ingestion was 0.12 f 0.02 ,umoI/l.
Overall no significant differences were found between the placebo and the phenformin days for the concentration of blood glucose, serum insulin, blood glycerol, total ketone bodies (sum of 3-hydroxybutyrate and acetoacetate concentrations) or the 3-hydroxybutyrate/acetoacetate ratio.
The mean concentrations of blood lactate, alanine and pyruvate were higher on the phenformin day. These increases were significant for hence resulting in a signilicant increase in the lactate/pyruvate ratio (11.3 f 0.3 vs 10.7 f 10.7 f 0.02; P < 0401). There was no correlation between plasma phenformin concentration and the changes in blood glucose, alanine, pyruvate and the lactate/pyruvate ratio produced by phenformin. In contrast there was a significant correlation between plasma phenformin and the change in blood lactate concentration (rs = 0.41; P < 0.01) (Fig. 1) .
Discussion
Beckmann (1966) reported phenformin concentrations of 1.7 pmol/l after 100 mg given orally with a half-life of 3.2 h. Plasma concentrations in the present study are compatible with these results although the timecourse is altered by the use of a sustained-release capsule. The present study demonstrates that some of the metabolic changes after phenformin in maturity-onset diabetic subjects (Nattrass et al., 1977) also occur in normal subjects after 50 mg of phenformin. The blood glucose concentration was not changed but the blood lactate, alanine and lactate/pyruvate ratio were significantly increased.
There was a correlation between plasma phenformin concentration and the effect upon blood lactate which has not previously been reported. The results suggest that the effect of phenformin upon blood lactate concentration may precede the effect upon blood glucose.
